Experimental chemo combo aims to boost transplant success in MDS
NCT ID NCT03572764
First seen Apr 15, 2026 · Last updated Jun 20, 2026 · Updated 10 times
Summary
This early-phase study tests CPX-351 (Vyxeos), a two-drug chemotherapy, in 20 adults aged 18-70 with higher-risk myelodysplastic syndrome (MDS) who are eligible for a stem cell transplant. The main goal is to see if the drug is safe and tolerable, with secondary goals of measuring remission rates and how many patients can proceed to transplant. Researchers will also collect blood, bone marrow, and skin samples to understand how the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CPX-351 (Vyxeos), a combination of two chemotherapy drugs (daunorubicin and cytarabine)
What this could lead to
If this works, it could help more high-risk MDS patients achieve remission and proceed to a stem cell transplant, potentially improving long-term outcomes.
What could go wrong
This is a very early (Phase 1) pilot study with only 20 participants, so results may not apply broadly. Chemotherapy carries risks like infection and organ damage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.